Company: PRGO
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0000950170-25-035751
Chunk: 92

Company: PERRIGO Co plc
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 92
---
 Adjusted                                                                              |     |                                       |     |    $1,808.5 |     |    $574.3 |     |             $352.0 |     |               $2.58 |
| As a % of reported net sales                                                          |     |                                       |     |       38.8% |     |     12.3% |     |               7.6% |     |                     |
| Diluted weighted average shares outstanding (in millions)                             |     |                                       |     |             |     |           |     |                    |     |                     |
| Reported                                                                              |     |                                       |     |             |     |           |     |              135.3 |     |                     |
| Effect of dilution as reported amount was a loss, while adjusted amount was income(4) |     |                                       |     |             |     |           |     |                1.4 |     |                     |
| Adjusted                                                                              |     |                                       |     |             |     |           |     |              136.7 |     |                     |

Note: Amounts may not add or recalculate due to rounding. Percentages are based on actuals. (1) Individual pre-tax line item adjustments have not been tax effected, as tax expense on these items are aggregated in the “Non-GAAP tax adjustments” line item. (2) During the twelve months ended December, 31, 2023, we determined goodwill related to our Rare Diseases reporting unit was impaired by $90.0 million and recorded the charge within our CSCI segment. (3) Non-GAAP tax adjustments for the twelve months ended December 31, 2023 are primarily due to $61.6 million of tax expense related to pre-tax non-GAAP adjustments, plus the removal of (1) $11.4 million of tax expense related to audit settlements (2) $2.1 million of tax expense related to valuation allowance and (3) $7.2 million of tax benefit related to tax law changes. (4) In the period of a net loss, diluted shares outstanding equal basic shares outstanding.

#### 94PERRIGO•2025 PROXY STATEMENT
Appendix A TABLE II PERRIGO COMPANY PLC RECONCILIATION OF NON-GAAP MEASURES SELECTED CONSOLIDATED INFORMATION (in millions) (unaudited)

| Consolidated Continuing Operations         | December 31, 
         2024 |
|:-------------------------------------------|-------------:|